Navigation Links
Researchers identify proteins in lung cancer cells that may provide potential drug targets
Date:11/24/2009

(Boston) Researchers from Boston University School of Medicine (BUSM) and the Boston University Biomedical Engineering Department have identified a number of proteins whose activation allows them to distinguish between cancer and normal cells with almost 97 percent accuracy. In addition, the BU researchers have developed a new computational strategy to analyze this data and specifically identify key biological pathways (molecular circuits) that are active in cancer and "dormant" in normal cells. The study which appears in the November 25th issue of PLoS ONE, will ultimately lead to the development of drugs specifically aimed to inhibit these proteins.

According to the BU researchers, there are many features that make cancer cells different from normal cells. They look different histologically, they proliferate and divide at different rates, they are immortal unlike normal cells, and are less communicative with their neighbor cells. They are also more "selfish" in refusing to commit suicide (programmed cell death) which normal cells do when their genomes become unstable.

Much of the cellular machinery involved with these biological processes is controlled by a command control and communication system called signal transduction. Signal transduction is in large part controlled by a process called phosphorylation. When a protein is phosphorylated it either becomes active or repressed depending on its special function. "Therefore, identifying the phosphorylation status of proteins in cancer cells versus normal cells provides us with a unique ability to understand and perhaps intervene with the command and control center of cancer cells," said co-senior author Simon Kasif, PhD, who is the co-director of the Center of Advanced Genomic Technology and a professor in the department of biomedical engineering at BU. "Drugs are most effective on cancers when they attack the proteins that are activated," he added.

While cancers are highly heterogeous in their make-up, the BU researchers believe that a drug that would target this collection of proteins would be effective treatment for most lung cancers.

"This is the first statistically validated phosphopeptide signature to diagnose any disease, much less cancer or lung cancer," explained senior co-author Martin Steffen, MD, PhD, an assistant professor of pathology and laboratory medicine at BUSM, and director, Proteomics Core Facility at BUSM.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research
2. Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps
3. Researchers identify role of gene in tumor development, growth and progression
4. On the trail of a vaccine for Lyme disease: Yale researchers target tick saliva
5. UCLA researchers create fly paper to capture circulating cancer cells
6. Researchers focus on helping dying patients take care of unfinished business
7. Mount Sinai researchers to test first gene therapy For Alzheimers patients
8. Wistar researchers show targeting normal cells in tumors slows growth
9. K-State researchers studying link between climate change and cattle nutritional stress
10. Cornell Researchers Identify a Weak Link in Cancer Cell Armor
11. Researchers notch a victory toward new kind of cancer drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... Lake City, Colo. (PRWEB) , ... April 21, 2017 , ... ... launch of the Flex House, the next project in the company’s esteemed VISION House ... to help homeowners use exactly the amount of resources they need to live affordably ...
(Date:4/21/2017)... Kong (PRWEB) , ... April 21, 2017 , ... The ... (U3DP), the first 3D printing facility among higher education institutions in Hong Kong to ... printing, in terms of the range and quantity of facilities in Hong Kong. ...
(Date:4/21/2017)... ... 2017 , ... Alive for Wellness is a group of clinical ... struggles. The Alive team uses advanced behavioral sciences treatment modalities to accomplish their ... mental health struggle is based on 10 modalities of treatment that include: ...
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens is honoured ... Trade, the UK’s most prestigious award for business success. The company has ... revenues and has grown by a total of 400% over the last six ...
(Date:4/21/2017)... ... 21, 2017 , ... BrightStar Care Salt Lake City, a home care agency ... (APCUT) and has appointed Rex Wheeler as its new Director of Business Development. “This ... and our ability to provide quality care to the community,” said Tammara Brown, owner ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... , Tenn. and DALLAS , April ... EndoStim, Inc., announced that the first patients in ... the EndoStim device in the Lower Esophageal Sphincter Stimulation ... a minimally-invasive implantable device designed to provide long-term reflux ... neurostimulation. GERD affects nearly 65 million people ...
(Date:4/19/2017)... 2017 Companion animal ... in pets such as canine, avian and feline. ... types such as Attenuated Live Vaccines, Conjugate Vaccines, ... and Recombinant Vaccines. Attenuated live vaccines are derived ... which have been weakend under laboratory conditions. Conjugate ...
Breaking Medicine Technology: